-+ 0.00%
-+ 0.00%
-+ 0.00%

SCIENTURE ISSUES SHAREHOLDER LETTER HIGHLIGHTING SEQUENTIAL REVENUE GROWTH, TWO FDA-APPROVED COMMERCIAL PRODUCTS, AND CONTINUED PROGRESS TOWARD PROFITABILITY IN 2027

Reuters·10/22/2026 12:05:00

Please log in to view news